

ForPatients

by Roche

Lymphoma

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Trial Status
Recruiting

Trial Runs In
1 Countries

Trial Identifier
NCT06624085 GO44900

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of the study is to evaluate glofitamab + gemcitabine + oxaliplatin in participants in the United States, including under-represented racial and ethnic populations, that have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT06624085 GO44900
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years

Healthy Volunteers
No
